New pill targets common Cancer-Causing gene in first human test
NCT ID NCT07252479
Summary
This is an early-stage trial testing a new oral drug called AN9025 in people with advanced solid tumors that have specific RAS gene mutations. The main goals are to find a safe dose, understand how the body processes the drug, and see if it shows any early signs of fighting the cancer. Participants will take the pill daily until their cancer worsens or side effects become too severe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS (PHASE 1) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.